CBAY

Cymabay Therapeutics
CBAY

Overview Fund Activity
Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

26 hedge funds and large institutions have $12.4M invested in Cymabay Therapeutics in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
26
Holders Change
-4
Holders Change %
-13.33%
% of All Funds
0.69%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.08%
New
4
Increased
6
Reduced
5
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.07M
2
UCFA
2
United Capital Financial Advisors
Texas
$52K
3
Renaissance Technologies
3
Renaissance Technologies
New York
$223K
4
BFA
4
BlackRock Fund Advisors
California
$115K
5
Citadel Advisors
5
Citadel Advisors
Florida
$47K

Top Sellers

1
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$1.6M
2
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$0
3
JGC
3
J. Goldman & Co
New York
$0
4
LOAMU
4
Lombard Odier Asset Management (USA)
New York
$1.14M
5
SM
5
Sabby Management
Florida
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
PVI
26
Pura Vida Investments
New York
– -$76K -56,000 Closed
TRCT
27
Tower Research Capital (TRC)
New York
– -$8K -5,777 Closed
Barclays
28
Barclays
United Kingdom
– -$1K -1,300 Closed
1
2